Isracann Biosciences Inc.

IPOT

CA46501D1087

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 08:11:13 05/04/2023 pm IST			5-day change	1st Jan Change
0.015 ^CAD	-.--%		-.--%	-.--%

26/04	Isracann Biosciences Inc. Announces Resignation of Directors	CI
23/01	Isracann Biosciences Inc. Announces Management Changes	CI

Atlas Cloud Enterprises Inc. Announces Resignations of Matthew Mckibbin, Chief Blockchain Officer, and Timothy Lewis, Chief Technology Officer

June 15, 2018 at 10:37 am IST

Atlas Cloud Enterprises Inc. announced the resignations of Matthew McKibbin, Chief Blockchain Officer, and Timothy Lewis, Chief Technology Officer, effective immediately.

Latest news about Isracann Biosciences Inc.

Isracann Biosciences Inc. Announces Resignation of Directors	26/04	CI
Isracann Biosciences Inc. Announces Management Changes	23/01	CI
Isracann Biosciences Inc. Announces Resignation of Yana Popova as CFO	23/01	CI
Isracann Biosciences Inc. announced that it has received CAD 0.025 million in funding	16/23/16	CI
Isracann Biosciences Inc. Appoints Ajay Singh Kaila as Interim CEO	23/23/23	CI
Isracann Biosciences Inc. Announces Resignation of Phil Floucault as Chief Executive Officer	18/23/18	CI
Isracann Biosciences Inc. Announces Resignation of Phil Floucault as Director	18/23/18	CI
Isracann Biosciences Inc. Announces Resignation of James Thompson as Chief Operations Officer	17/23/17	CI
Isracann Biosciences Inc. Announces the Resignation of Irit Arbel as Director	21/22/21	CI
Isracann Biosciences Inc. Reports Earnings Results for the First Quarter Ended August 31, 2022	08/22/08	CI
Isracann Biosciences Inc. Auditor Raises 'Going Concern' Doubt	30/22/30	CI
Isracann Biosciences Inc. Reports Earnings Results for the Full Year Ended May 31, 2022	30/22/30	CI
Isracann Bioscience Inc. Announces Facilitated Genetics Arrive in Israel	28/22/28	CI
Isracann Bioscience Facilitates Cannabis Genetics Shipment to Israel	14/22/14	CI
Isracann Inks Distribution Agreement with Pure Integrative Pharmacy for Praesidio Health Products	01/22/01	MT
Isracann Biosciences Inc. Signs Distribution Agreement with Pure Integrative Pharmacy	01/22/01	CI
Isracann Biosciences Inc. Appoints Mark Rypien to Its Advisory Board	23/22/23	CI
Isracann Biosciences Completes First Tranche of Private Placement	03/22/03	MT
Isracann Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	28/22/28	CI
Isracann Biosciences Inc. Announces Executive Changes	20/22/20	CI
Isracann Biosciences Renews Leadership, Announces $3 Million Financing	18/22/18	MT
Isracann Biosciences Inc. Announces Executive Changes	15/22/15	CI
Isracann Biosciences Inc. announced that it expects to receive CAD 2.940794 million in funding	15/22/15	CI
Isracann Biosciences Inc. Appoints George Vrabec to the Position of Director of Natural Health Products	13/22/13	CI
Isracann Biosciences Inc. completed the acquisition of Praesidio Health Inc.	12/22/12	CI

Chart Isracann Biosciences Inc.

Duration

Period

More charts

Isracann Biosciences Inc. is a Canada-based cannabis company. The principal business focus of the Company is medical cannabis cultivation and distribution to provide products to the Israeli medical cannabis market, and to develop and validate Natural Health Products (NHP), through the Companyâs operating subsidiaries. The Company's segments include Head Office, Medical Cannabis and Natural Health Product. The Company aims to commercialize natural health medicines in Canada and to leverage agreements within Israel for import/export opportunities and medicinal marijuana cultivation. The Company's subsidiaries include Isracann Holdings Inc., Praesidio Health Inc., Isracann Biosciences Capital Ltd., Isracann Operations Ltd., Isracann Development Ltd., Isracann Agritech Ltd., Isracann Administrative Services Ltd. and others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
ISRACANN BIOSCIENCES INC.	-.--%	1.94M
DONG-E-E-JIAO CO.,LTD.	+37.29%	6.09B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.28%	4.14B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+4.52%	3.23B
TASLY PHARMACEUTICAL GROUP CO., LTD	-18.16%	2.83B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-7.70%	2.39B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	1.9B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.05%	1.57B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-15.56%	1.55B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.62%	1.5B